The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C02 | Antihypertensives | |
| 3 | C02A | Antiadrenergic agents, centrally acting | |
| 4 | C02AC | Imidazoline receptor agonists | |
| 5 | C02AC01 | Clonidine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 0.45 mg |
| PAREN - Parenteral | 0.45 mg |
| Active Ingredient | Description | |
|---|---|---|
| Clonidine |
Clonidine has been shown to have both central and peripheral sites of action. With long-term treatment clonidine reduces the responsiveness of peripheral vessels to vasoconstrictor and vasodilator substances and to sympathetic nerve stimulation. Early in treatment, however, blood pressure reduction is associated with a central reduction of sympathetic outflow and increased vagal tone. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CATAPRES Solution for injection | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| CATAPRES Tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| ONYDA Extended-release oral suspension | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
